Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy

Martin S. Maron(Tufts Medical Center), Theodore P. Abraham(University of California, San Francisco), Stephen B. Heitner(Baim Institute for Clinical Research), Aslan T. Turer(Southwestern Medical Center), Sara Saberi(Michigan Medicine), Iacopo Olivotto, Amy Wohltman(Baim Institute for Clinical Research), Hugh Watkins(Centre for Human Genetics), Christopher M. Kramer(American College of Cardiology), Anjali Owens(University of Pennsylvania), Caroline Coats(Baim Institute for Clinical Research), Albree Tower‐Rader(Massachusetts General Hospital), Timothy C. Wong(University of Pittsburgh Medical Center), Neal K. Lakdawala(Brigham and Women's Hospital), Scott D. Solomon(Brigham and Women's Hospital), Pablo García‐Pavía(Universidad Francisco de Vitoria), Sharon L. Paige(Cytokinetics (United States)), Ahmad Masri(Oregon Health & Science University), Fady I. Malik(Baim Institute for Clinical Research), Stuart Kupfer(Baim Institute for Clinical Research), Florian Rader(Cedars-Sinai Medical Center), Michael A. Fifer(Massachusetts General Hospital), Lisa Meng(Baim Institute for Clinical Research), Lubna Choudhury(Baim Institute for Clinical Research), Sherif F. Nagueh(Houston Methodist), Andrew Wang(Duke University Hospital), Roberto Barriales‐Villa
Journal of the American College of Cardiology
January 1, 2023
Cited by 192


Related Papers